Is Arbutus Biopharma Corp (ABUS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 14.1% / 30% | 0.3% / 30% | 106.71% / 5% | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 14.1% / 33% | 0.3% / 33% | 106.71% / 5% | ✗ NOT HALAL |
| MSCI | 1.0% / 33% | 93.1% / 33% | 1.8% / 33% | 106.71% / 5% | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 14.1% / 33% | 0.3% / 33% | 106.71% / 5% | ✗ NOT HALAL |
| FTSE | 1.0% / 33% | 93.1% / 33% | 1.8% / 50% | 106.71% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -79.2% | |
| Operating Margin | -727.3% | |
| Net Margin | -237.9% | |
| Return on Equity (ROE) | -38.5% | |
| Return on Assets (ROA) | -14.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$65M |
| Free Cash Flow | -$65M |
| Total Debt | $1M |
| Debt-to-Equity | 5.5 |
| Current Ratio | 15.7 |
| Total Assets | $132M |
Price & Trading
| Last Close | $4.45 |
| 50-Day MA | $4.31 |
| 200-Day MA | $4.12 |
| Avg Volume | 2.1M |
| Beta | 0.7 |
|
52-Week Range
$2.71
| |
About Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Arbutus Biopharma Corp (ABUS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Arbutus Biopharma Corp is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Arbutus Biopharma Corp's debt ratio?
Arbutus Biopharma Corp's debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.0%.
What are Arbutus Biopharma Corp's key financial metrics?
Arbutus Biopharma Corp has a market capitalization of $839M, and revenue of $6M. The company maintains a gross margin of -79.2% and a net margin of -237.9%. Return on equity stands at -38.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.